The targeted inhibition of CXCR2 eliminates CML stem cells and overcomes Ponatinib intolerance via the PI3K/Akt/mTOR and CD26 pathways. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.